{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T08:22:26Z","timestamp":1791793346795,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ccl.2019.07.004","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T16:38:11Z","timestamp":1566837491000},"page":"399-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Fluoropyrimidine-Associated Cardiotoxicity"],"prefix":"10.1016","volume":"37","author":[{"given":"Jaya","family":"Kanduri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Alberto","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Godishala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Asnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccl.2019.07.004_bib1","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2019.07.004_bib2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5603\/CJ.2012.0084","article-title":"5-Fluorouracil induced cardiotoxicity: review of the literature","volume":"19","author":"Sorrentino","year":"2012","journal-title":"Cardiol J"},{"key":"10.1016\/j.ccl.2019.07.004_bib3","first-page":"2346","article-title":"Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxy-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole","volume":"51","author":"Curtin","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.ccl.2019.07.004_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management","volume":"18","author":"Layoun","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ccl.2019.07.004_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000072334","article-title":"High incidence of angina pectoris in patients treated with 5-fluorouracil","volume":"65","author":"Wacker","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.ccl.2019.07.004_bib6","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2019.07.004_bib7","first-page":"44","article-title":"Fluoropyrimidine cardiotoxicity: time for contemporaneous appraisal","volume":"18","author":"Upshaw","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ccl.2019.07.004_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1989.7.4.509","article-title":"Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study","volume":"7","author":"Rezkalla","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2019.07.004_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2007","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.ccl.2019.07.004_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003495-199957040-00003","article-title":"Cardiotoxicity of the antiproliferative compound fluorouracil","volume":"57","author":"Becker","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ccl.2019.07.004_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.tpj.6500012","article-title":"Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy","volume":"1","author":"Pullarkat","year":"2001","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.ccl.2019.07.004_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity","volume":"81","author":"Diasio","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ccl.2019.07.004_bib13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6600208","article-title":"Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene","volume":"86","author":"Maring","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ccl.2019.07.004_bib14","first-page":"215","article-title":"Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene","volume":"10","author":"Shahrokni","year":"2009","journal-title":"J\u00a0Pancreas"},{"key":"10.1016\/j.ccl.2019.07.004_bib15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/oxfordjournals.eurheartj.a059919","article-title":"Coronary artery spasm induced by fluorouracil","volume":"12","author":"Luwaert","year":"1991","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccl.2019.07.004_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5152\/akd.2010.147","article-title":"Two cases of coronary vasospasm induced by 5-fluorouracil","volume":"10","author":"Atar","year":"2010","journal-title":"Anadolu Kardiyol Derg"},{"key":"10.1016\/j.ccl.2019.07.004_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/107327480401100107","article-title":"5-Fluorouracil-induced coronary vasospasm","volume":"11","author":"Shoemaker","year":"2004","journal-title":"Cancer Control"},{"key":"10.1016\/j.ccl.2019.07.004_bib18","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.15420\/ahhj.2010.8.2.111","article-title":"Angina induced by 5-fluorouracil infusion in a patient with normal coronaries","volume":"8","author":"Tajik","year":"2010","journal-title":"Am Heart Hosp J"},{"key":"10.1016\/j.ccl.2019.07.004_bib19","first-page":"3028","article-title":"In\u00a0vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ccl.2019.07.004_bib20","first-page":"805","article-title":"The\u00a0appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits","volume":"10","author":"Cwikiel","year":"1996","journal-title":"Scanning Microsc"},{"key":"10.1016\/j.ccl.2019.07.004_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ccl.2019.07.004_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/oxfordjournals.annonc.a058084","article-title":"Very high endothelin plasma levels in patients with 5-FU cardiotoxicity","volume":"3","author":"Thyss","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ccl.2019.07.004_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0021-5198(19)52945-6","article-title":"Cardiotoxic effects of 5-fluorouracil in the Guinea pig","volume":"30","author":"Matsubara","year":"1980","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.ccl.2019.07.004_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1191\/0960327106ht628oa","article-title":"Cardiac lesions induced by 5-fluorouracil in the rabbit","volume":"25","author":"Tsibiribi","year":"2006","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.ccl.2019.07.004_bib25","doi-asserted-by":"crossref","first-page":"e0115686","DOI":"10.1371\/journal.pone.0115686","article-title":"Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy, and ROS production in endothelial cells and cardiomyocytes","volume":"10","author":"Focaccetti","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ccl.2019.07.004_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/009841000156709","article-title":"Reduced antioxidant defense capacity in myocardial tissue from Guinea pigs treated with 5-fluorouracil","volume":"59","author":"Durak","year":"2000","journal-title":"J\u00a0Toxicol Environ Health A"},{"key":"10.1016\/j.ccl.2019.07.004_bib27","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1200\/JCO.2011.38.5278","article-title":"Takotsubo cardiomyopathy and fluorouracil: case report and review of the literature","volume":"30","author":"Grunwald","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2019.07.004_bib28","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1021\/ci0501746","article-title":"Effects of 5-fluorouracil on erythrocytes in relation to its cardiotoxicity: membrane structure and functioning","volume":"45","author":"Spasojevic","year":"2005","journal-title":"J\u00a0Chem Inf Model"},{"key":"10.1016\/j.ccl.2019.07.004_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0267659111410347","article-title":"Is 5-fluorouracil-induced vasospasm a Kounis syndrome? A diagnostic challenge","volume":"26","author":"Karabay","year":"2011","journal-title":"Perfusion"},{"key":"10.1016\/j.ccl.2019.07.004_bib30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.21037\/jgo.2017.09.07","article-title":"Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm","volume":"8","author":"Clasen","year":"2017","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.ccl.2019.07.004_bib31","first-page":"1675","article-title":"Cardiac toxicity of 5-fluorouracil: review of the literature, 5 new cases","volume":"17","author":"Clavel","year":"1988","journal-title":"Presse Med"},{"key":"10.1016\/j.ccl.2019.07.004_bib32","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1200\/jco.2009.27.15_suppl.9616","article-title":"Vistonuridine: an orally administered, life-saving antidote for 5-fluorouracil (5FU) overdose","volume":"155","author":"Borstel","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2019.07.004_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.30321","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","volume":"123","author":"Ma","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ccl.2019.07.004_bib34","first-page":"43","article-title":"Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer","volume":"2","author":"Marsh","year":"2002","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ccl.2019.07.004_bib35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/sj.bjc.6604536","article-title":"A\u00a0randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer","volume":"99","author":"Lee","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ccl.2019.07.004_bib36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1249\/01.MSS.0000117130.91142.38","article-title":"Training enhances vascular relaxation after chemotherapy-induced vasoconstriction","volume":"36","author":"Hayward","year":"2004","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.ccl.2019.07.004_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ccl.2019.07.004_bib38","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ccl.2019.07.004_bib39","doi-asserted-by":"crossref","first-page":"e14057","DOI":"10.1097\/MD.0000000000014057","article-title":"Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer, a case report","volume":"98","author":"Peng","year":"2019","journal-title":"Medicine (Baltimore)"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865119300530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865119300530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:51:43Z","timestamp":1760007103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865119300530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0733865119300530"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2019.07.004","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluoropyrimidine-Associated Cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2019.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}